Frequency of primary outcome was 27.6 and 23.4 percent in glyburide and insulin groups, respectively

Findings show MHO is transient, so not a reliable predictor of lower cardiovascular risk in the future

Major adverse CV and cerebrovascular events with noncardiac sx have also increased in DM patients

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Review: Need …